How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,331 results for

Myocardial Infarction Stabilization

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3121. Our experiences for off-pump coronary artery bypass grafting to the circumflex system. (Abstract)

. Complications included respiratory insufficiency (0.8%), renal dysfunction (7%), and sternal wound infection (0.8%). Blood transfusions were required in 10 patients (8%). No patient suffered perioperative myocardial infarction or stroke. No operation was converted to cardiopulmonary bypass. There was no operative death. Predischarge angiography demonstrated a 99% patency rate.With our techniques and instruments, off-pump coronary revascularizaion of the circumflex area may be performed safely to achieve (...) reconstruction of the circumflex artery are the subjects of this study. There were no exclusion criteria. A series of techniques and instruments were developed to provide access to the circumflex area while hemodynamic stability was preserved, including the left pericardial traction technique, compression of the right pericardium, a right sternal retractor, and a type of shunt tube.Patients received an average of 3.2 grafts (range, 2 to 6). Complete revascularization was achieved in 95% of the cases

2003 Annals of Thoracic Surgery

3122. Short-term noninvasive pressure support ventilation prevents ICU admittance in patients with acute cardiogenic pulmonary edema. (Abstract)

and were admitted to the ICU.The included optimal length of intervention, the avoidance of ICU admittance, the incidence of myocardial infarction, and predictive lack of response criteria.Patients completed the trial (mean [+/- SD] duration, 96 +/- 40 min). None of the responders (43 patients; 74%) was subsequently ventilated or was admitted to the ICU. Two new episodes of myocardial infarction were observed. Thirteen of 58 patients died. A mean arterial pressure of < 95 mm Hg (odds ratio [OR], 10.6 (...) variables.Prospective inception cohort study.ED of a university hospital.Fifty-eight consecutive patients with cardiogenic pulmonary edema who had been unresponsive to medical treatment and were admitted between January 1999 and December 2000.Pressure support ventilation was instituted through a full-face mask until the resolution of respiratory failure. A 15-min "weaning test" was performed to evaluate clinical stability. Responder patients were transferred to a medical ward. Nonresponding patients were intubated

2003 Chest

3123. [Effects of prostacyclin (PGI2) on tachycardic heart arrhythmias following aortocoronary venous bypass operations]. (Abstract)

and/or by an antiarrhythmic effect on the myocardium. Whether the antiarrhythmic effect of PGI2 on the myocardium is indirect (reduction of microcirculatory disorders produced by inhibition of platelet aggregation) or direct (electrical stabilization of the myocardial cell membrane), is the subject of further investigations. (...) [Effects of prostacyclin (PGI2) on tachycardic heart arrhythmias following aortocoronary venous bypass operations]. In a prospective double-blind study of 40 male patients requiring aorto-coronary bypass surgery, a dose of 8 ng/kg/min of PGI2 was infused throughout extracorporeal circulation (ECC) (control group: glycine buffer). Between the two treatment groups there was no difference in preoperative hemodynamic parameters, number of preoperative infarctions, or number of implantated aorto

1986 Herz

3124. Additional molsidomine in refractory unstable angina pectoris. (Abstract)

myocardial infarction (n = 3). Two patients had angiographically documented severe coronary spasms. Patients entered the study if coronary bypass surgery or PTCA could not be performed within 3 days after angiography (n = 9) or was not feasible due to anatomical or technical reasons (n = 6), concomitant malignant disease (n = 2), or age greater than 75 years (n = 3). All patients received molsidomine orally 12 to 24 mg/day. In 15 of the 20 patients molsidomine was given i.v. initially, starting with 20 (...) mg i.v., followed by infusion of 1 to 4 mg/hour. Heart rate and blood pressure did not change significantly, and eight patients had a slight decrease of systolic and diastolic blood pressure. Severe adverse effects did not occur, and moderate headaches were reported by five patients. In 13 patients, unstable angina could be stabilized, and they remained free of resting angina; five had a marked reduction of the frequency of anginal attacks. In two patients, molsidomine was without demonstrable

1991 Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy

3125. Clinical characteristics and current management of medically refractory unstable angina. Full Text available with Trip Pro

ejection fractions (EF) of less than 0.40. Twenty-four patients were greater than 65 years of age, and 53 had associated major diseases. Forty-eight patients (Group I) had no evidence of myocardial infarction in the 30 days before catheterization, whereas 52 patients had an infarction precipitating the unstable angina within the preceding 30 days (Group II). Emergent coronary artery bypass grafting was performed in all 100 patients irrespective of ventricular function, hemodynamic status, or coronary (...) anatomy. Management protocols included prompt surgical intervention, preoperative stabilization with the balloon pump in LM or TVD, meticulous myocardial protection, and complete coronary revascularization. An average of 3.6 grafts were placed in each patient. There were two hospital deaths in Group I, and two in Group II. Two-year survival was 90% in Group I and 88% in Group II, and 81% of surviving patients were NYHA Class I or II. Thus, refractory UA denotes particularly severe coronary disease

1984 Annals of Surgery

3126. Mechanical Circulatory Assist Devices Full Text available with Trip Pro

be weaned from circulatory support. Patients suffering cardiogenic shock due to acute myocardial infarction can be stabilized with circulatory assist for medical and surgical treatment. In addition, mechanical circulatory assist devices can serve as a bridge for patients awaiting cardiac transplantation. (...) Mechanical Circulatory Assist Devices Cardiogenic shock occurs in about 10% of the 1.5 million patients who suffer myocardial infarction and in approximately 1% of the 200,000 patients who undergo open-heart surgery each year. The ventricular assist device decreases the workload of the failing ventricles and increases the blood flow through the coronary system. Recovery of failing myocardium after mechanical circulatory assistance has been well documented; however, the mechanisms

1987 Texas Heart Institute Journal

3127. Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

infections are eligible only if evidence of response to antifungal medications is documented and fever does not exceed 38C for at least 2 days. Inability to give informed consent because of psychiatric problems or other serious medical problems. Pregnant or nursing women. Patients with documented CNS leukemia or leukemia with CNS symptoms. Patients who have had a myocardial infarction within the past six months. Patients with severe penicillin allergy (anaphylaxis). Not fully recovered from toxic effects (...) to initiating the treatment. The WBC count must be stabilized below this level for at least three days by leukopheresis or hydroxyurea. Hydroxyurea must be discontinued one day prior to initiation of DT388GMCSF treatment. Patients must have creatinine < 1.6 times ULN: bilirubin <1.6 times ULN; SGPT < 2.6 x ULN; albumin > 3 gm/dl; adequate cardiac function (EF >44%), oxygen saturation > 92% without exogenous oxygen administered. Patients must be willing to be treated at M D Anderson Cancer Center. Women

2003 Clinical Trials

3128. Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer

or fungal infections requiring treatment. Patients with serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the investigator, would not permit adequate follow-up and compliance with the study protocol. Use of any investigational agent within four weeks of study treatment. Prior gene therapy. History of myocardial infarction within 6 months, angina within the past 6 months, or a history of arrhythmias on active therapy (...) of normal. FEV1 and corrected DLCO of >/= 40% of predicted. Patients with asymptomatic brain metastases that have been treated are eligible if the following criteria are met: No history of seizures in the preceding 6 months. Definitive treatment must have been completed ≥4weeks prior to registration. Subjects must be off steroids that were being administered because of brain metastases or related symptoms for ≥2 weeks. Post-treatment imaging within 2 weeks of registration must demonstrate stability

2003 Clinical Trials

3129. Postural Control in the Elderly

CRITERIA: Subjects will be enrolled in this balance study if they are within the range of 20-90 years old; in good health; report no difficulties or need for help in performing self-care or instrumental activities of daily living; and are able to walk for at least 400 meters. EXCLUSION CRITERIA: We will be unable to study people who have substantial congitive impairment based on mental status screening tests; history of cardiovascular disease (including angina, myocardial infarction, congestive heart (...) and backward directions. When the subject recognizes an unstable position in the movements, he or she presses a computer mouse. An EEG records brain activity during the task, which lasts up to 2 hours. Condition or disease Musculoskeletal Physiology Healthy Detailed Description: A number of studies have explored the role of visual, vestibular and somatosensory systems in the control of upright posture. However, the cortical control of postural stability, in general, and the role of higher cognitive

2003 Clinical Trials

3130. Warfarin and Antiplatelet Therapy in Chronic Heart Failure

myocardial infarction and nonfatal stroke [ Time Frame: 30 months intake; 12-42 months follow-up ] The primary safety end point was major bleeding episodes, defined as bleeding episodes leading to death or disability (including loss of neurological or special senses function), requiring surgical intervention, or associated with an acute decline of hemoglobin 2gm/dl or transfusion of >1 U packed red cells or whole blood. Eligibility Criteria Go to Information from the National Library of Medicine Choosing (...) , monitored by measurements at 6 week intervals after initial titration and stabilization. Active Comparator: 2 Aspirin 182 mg Drug: Aspirin an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner. Active Comparator: 3 Clopidogrel 75 mg Drug: Clopidogrel 75 (an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner) Outcome Measures Go to Primary Outcome Measures : acomposite of mortality, nonfatal

2000 Clinical Trials

3131. Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

times ULN Cardiovascular: No uncontrolled high blood pressure No unstable angina, symptomatic congestive heart failure, or serious cardiac arrhythmia No New York Heart Association class III or IV heart disease No history of cardiac toxicities with prior fluorouracil and leucovorin calcium No myocardial infarction within the past 6 months Pulmonary: No interstitial pneumonia or extensive and symptomatic fibrosis of the lung Other: Not pregnant or nursing Negative pregnancy test Fertile patients must (...) symptomatic worsening, time to disease progression, onset and duration of complete and partial responses, and duration of disease stabilization in patients treated with these regimens. III. Determine the safety profile of these regimens in these patients. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to Karnofsky performance status (50-60% vs 70-100%), number of metastatic organs (1 vs 2 or more), and LDH value (up to 1.5 times upper limit of normal (ULN

2001 Clinical Trials

3132. Children's Activity and Nutrition III

for blood pressure (BP) control within the context of ethnicity and family history of early myocardial infarction (MI), defined as having a parent or grandparent with an MI at less than 55 years of age and a family history. Blacks have a higher mortality rate through middle adulthood than whites from coronary heart disease (CHD), the leading causes of death in the United States. Blacks have been found to exhibit greater cardiovascular (CV) response to stress (i.e., reactivity), a potential risk factor (...) artery wall elasticity and endothelial dependent arterial dilation up to 11 years later after controlling for other expected predictors (i.e., age, gender, ethnicity, resting BP, adiposity, ambulatory BP); 2) the influence of ethnicity, family history and a select group of moderator variables (i.e., environmental stress, anger and John Henryism coping styles, aerobic fitness on youth's cardiovascular (CV) reactivity; and 3) the stability of CV reactivity and a 24- hour ambulatory BP from childhood

2000 Clinical Trials

3133. Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression

diabetic complications but which have not progressed to end-stage renal failure Failure of intensive insulin management, as judged by an endocrinologist independent of study investigators EXCLUSION CRITERIA: Significant cardiac disease as defined by: a) a history of a myocardial infarction with the past 6 months or b) coronary angiographic evidence of non-correctable arteriopathy, or c) evidence of ischemia on a functional cardiac examination Active alcoholism or other substance abuse (including (...) , with the dosages adjusted to account for the transplanted islets. They will take Daclizumab every 2 weeks, and FK506 and rapamycin daily. Blood tests to follow how much of these drugs are in the blood stream will be performed daily at first and then weekly after blood levels of these drugs stabilize. They will be given antibiotics to prevent infections. The arginine test will be repeated 2 weeks after the transplant and periodically thereafter. Blood will be drawn weekly to check drug levels, and monthly

2000 Clinical Trials

3134. MYOHEARTâ„¢ (Myogenesis Heart Efficiency and Regeneration Trial)

Congestive Heart Failure Coronary Artery Disease Myocardial Infarction Drug: MyoCell™ Device: MyoCath™ Phase 1 Detailed Description: A very promising approach to reversal or stabilization of the post-infarct remodeling process is the direct injection of regenerative cells into the myocardial infarct scar. Such cell-based therapy for cardiac repair is called "cellular cardiomyoplasty". The MyoCell™ implantation using the MyoCath™ delivery catheter system may have the potential to add a new dimension (...) . Information provided by: Bioheart, Inc. Study Details Study Description Go to Brief Summary: The MyoCell™ implantation using the MyoCath™ delivery catheter system may have the potential to add a new dimension to the management of post-infarct deterioration of cardiac function in subjects with congestive heart failure. Based on pre-clinical studies, implantation of autologous skeletal myoblasts may lead to replacement of non-functioning myocardial scar with functioning muscle and improvement in myocardial

2003 Clinical Trials

3135. Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes

of insulin provision. B. Secondary Aims The secondary aims of the BARI 2D trial include: a) comparing the death, myocardial infarction or stroke combined endpoint event rate between the revascularization versus medical therapy groups and between the insulin sensitization versus insulin provision groups; b) comparing rates of myocardial infarction, other ischemic events, angina and quality of life associated with each revascularization and hyperglycemia management strategy; c) evaluating the relative (...) , Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers Outcome Measures Go to Primary Outcome Measures : Number of Participants With All-Cause Mortality [ Time Frame: five years ] Secondary Outcome Measures : Number of Participants With Death, Myocardial Infarction, or Stroke [ Time Frame: five years ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members

2000 Clinical Trials

3136. Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

or coagulopathy or need for full-dose anticoagulation Hepatic Bilirubin less than 3 times upper limit of normal (ULN) Alkaline phosphatase less than 3 times ULN Renal Creatinine less than 2 times ULN Protein < 0.5 g/24 hr urine collection if proteinuria positive by dipstick Cardiovascular No uncontrolled congestive heart failure No uncontrolled angina pectoris No uncontrolled hypertension No uncontrolled arrhythmia No myocardial infarction within the past 12 months No cerebrovascular accident or transient (...) Chemotherapy No prior chemotherapy except for metastatic disease confined to the liver Prior fluorouracil, leucovorin calcium, and oxaliplatin allowed if administered for at least 3 courses (2 weeks each) but no longer than 3 months with at least stabilization of disease achieved Prior adjuvant chemotherapy for primary cancer allowed except for patients who received oxaliplatin and have been diagnosed with metastatic disease within 12 months after completion of adjuvant treatment Endocrine therapy

2002 Clinical Trials

3137. Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy

during the study is permitted. Allergy to sulpha-containing compounds, NSAIDs, or demonstration o the aspiring triad. History of kidney disease (creatinine level greater than 2.5 dL, need for dialysis, or microalbuminurea). Liver disease. Concurrent use of warfarinor known bleeding diathesis. History of inflammatory bowel disease. Concurrent use of lithium. History of peptic ulcer within 1 year prior to enrollment. History of myocardial infarction 2 years prior to enrollment. Contacts and Locations (...) provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration (AMD) who are receiving photodynamic therapy, or PDT (also called cold laser treatment). The macula is the part of the retina in the back of the eye that determines central or best vision. AMD can severely impair

2002 Clinical Trials

3138. Chemotherapy in Treating Women With Metastatic Breast Cancer

than 1.5 mg/dL SGOT or SGPT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 months Neurologic: No history of an existing grade 3-4 peripheral neuropathy of any etiology Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No allergy to camptothecin (...) therapy (e.g., patients with disease that is primarily resistant to hormonal therapy, patients without prior partial response, or stabilization of disease lasting less than 6 months) Patients with new or extensive visceral metastases Patients with rapidly progressive or symptomatic metastases during hormonal therapy Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No prior radiotherapy to greater than 50% of bone marrow No concurrent radiotherapy

2000 Clinical Trials

3139. TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min No gross hematuria Cardiovascular: No uncontrolled cardiac arrhythmia No myocardial infarction within the past 6 months Other: No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer No severe concurrent disease, infection, or comorbidity (...) the 12-month survival of patients with advanced non-small cell lung cancer treated with TLK286. II. Determine the overall survival of patients treated with this drug. III. Determine the objective response rate, duration of objective response, time to tumor progression, and disease stabilization in patients treated with this drug. IV. Determine the safety of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive TLK286 IV over 30 minutes on day 1. Courses repeat every 21

2002 Clinical Trials

3140. Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

times ULN (no greater than 5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No unstable angina No New York Heart Association class III or IV congestive heart failure No serious cardiac arrhythmia No history of cardiac toxicity from fluorouracil/leucovorin calcium No myocardial infarction within past 6 months Pulmonary: No interstitial pneumonia or extensive and symptomatic fibrosis of the lung Other: No uncontrolled predisposing colonic (...) metastatic colorectal cancer. Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: irinotecan hydrochloride Drug: oxaliplatin Phase 3 Detailed Description: OBJECTIVES: Compare the overall survival of patients with metastatic colorectal cancer treated with irinotecan with or without oxaliplatin. Compare the response rate, time to tumor-related worsening of symptoms, time to disease progression, onset and duration of responses, and duration of disease stabilization in these patients

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>